Article
Selective Janus kinase inhibition preserves interferon-λ–mediated antiviral responses
14 May 2021
Abstract excerpt
Inflammatory diseases are frequently treated with Janus kinase (JAK) inhibitors to diminish cytokine signaling. These treatments can lead to inadvertent immune suppression and may increase the risk of viral infection. Tyrosine kinase 2 (TYK2) is a JAK family member required for efficient type I interferon (IFN-α/β) signaling. We report here that selective TYK2 inhibition preferentially blocked potentially...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
